Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
about
Animal models of hemophiliaCardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failureAdeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liverAn Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T CellsAdeno-associated virus capsid antigen presentation is dependent on endosomal escape.Evading the immune response upon in vivo gene therapy with viral vectors.Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.Enhanced T cell function in a mouse model of human glycosylation.Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.Adeno-Associated Virus Gene Therapy for Liver Disease.Antigenic and immunosuppressive properties of a trimeric recombinant transmembrane envelope protein gp41 of HIV-1Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes.The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.Inhibition of antigen presentation during AAV gene therapy using virus peptides.Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions In Vivo.Parvoviruses: structure and infection
P2860
Q27012571-98EBC2B9-2A38-432D-9420-B26B7EBFE1A0Q27691424-A963D8A2-510C-4795-9CC3-DB23BDDCBD1DQ34621723-E01AFEE3-E5DD-44E2-A27F-2356D87E6624Q34843835-7C6878D8-FD23-4F1F-9B10-C5A4B4953515Q36365372-D4A47355-982B-4952-BE60-5B3737382EF2Q36638203-54FD564E-F66C-4829-8CBD-F36BBB5DDB7AQ36644230-66E671DA-377E-4179-BF83-A1F4604CB7E9Q36709834-3F1E9EFB-AF15-4FBE-B841-56EAAEE07237Q36848699-99739DED-64C6-4FEF-AE9F-7F905B954A6BQ36951529-21202B7F-46AE-49B6-B309-E16A80BE5039Q38191212-AFEA3075-7AB0-4533-9D6F-CB351964D48BQ38789554-80D19829-4A50-4561-9B48-37AC31A3D073Q38914831-24747A57-72AD-4AEA-A5B6-DBB139CFB2D5Q39628648-504ED406-62AE-45C2-9C53-D9A21522AD7EQ42261520-A0BF0B6E-F1D7-4A04-BE66-01B56039E7B6Q47260510-BE00A4AE-0A99-4ECE-B606-71409FEA1E1CQ54221427-1C0F04E9-B892-45FA-AFBA-0C65E47DE541Q56115905-17F5F094-8FDC-4D95-86A9-C010D38AAED3
P2860
Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@en
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@nl
type
label
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@en
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@nl
prefLabel
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@en
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@nl
P2093
P2860
P921
P356
P1433
P1476
Cytotoxic-T-lymphocyte-mediate ...... d virus type 2 vector in vivo.
@en
P2093
Aravind Asokan
Chengwen Li
Kevin Goudy
Matt Hirsch
Nina DiPrimio
R Jude Samulski
Roland Tisch
P2860
P304
P356
10.1128/JVI.00278-09
P407
P577
2009-04-15T00:00:00Z